Quantification of BIM mRNA In Circulating Tumor Cells Of Osimertinib-treated Patients with EGFR Mutation-positive Lung Cancer

被引：0

作者：

Isobe, K. ^{[1
]}

Kobayashi, H. ^{[1
]}

Isshiki, T. ^{[1
]}

Sakamoto, S. ^{[1
]}

Takai, Y. ^{[1
]}

Tomida, T. ^{[2
]}

Adachi-Akahane, S. ^{[2
]}

Kishi, K. ^{[1
]}

机构：

[1] Toho Univ, Sch Med, Dept Resp Med, Tokyo, Japan

[2] Toho Univ, Sch Med, Dept Physiol, Tokyo, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P34.07

引用

页码：S417 / S418

页数：2

共 50 条

[21] Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers
Akita, Takahiro
Ariyasu, Ryo
Kakuto, Sho
Miyadera, Keiki
Kiritani, Ayu
Tsugitomi, Ryosuke
Amino, Yoshiaki
Uchibori, Ken
Kitazono, Satoru
Yanagitani, Noriko
Tasaka, Sadatomo
Nishio, Makoto
THORACIC CANCER, 2024, 15 (10) : 788 - 796
[22] Concomitant Driver Mutation Determines Tumor Growth in EGFR Mutation-Positive Lung Adenocarcinoma
Nagayama, Kazuhiro
Karasaki, Takahiro
Kuwano, Hideki
Nitadorti, Jun-Ichi
Sato, Masaaki
Anraku, Masaki
Matsushita, Hirokazu
Kakimi, Kazuhiro
Nakajima, Jun
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S508 - S509
[23] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Ramalingam, Suresh S.
Yang, James C-H
Lee, Chee Khoon
Kurata, Takayasu
Kim, Dong-Wan
John, Thomas
Nogami, Naoyuki
Ohe, Yuichiro
Mann, Helen
Rukazenkov, Yuri
Ghiorghiu, Serban
Stetson, Daniel
Markovets, Aleksandra
Barrett, J. Carl
Thress, Kenneth S.
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
[24] Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
Pan, Jie
Cai, Xiaoping
Cao, Zhuo
Pan, Jiongwei
Zheng, Hao
PHARMACOLOGY, 2023, 108 (01) : 8 - 16
[25] Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
Yoshida, H.
Kim, Y. H.
Ozasa, H.
Nagai, H.
Sakamori, Y.
Tsuji, T.
Nomizo, T.
Funazo, T.
Yasuda, Y.
Hirai, T.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2416 - S2416
[26] Validation of article analysis by ChatGPT: Using a cohort of patients with EGFR mutation-positive non-small cell lung cancer treated with first-line osimertinib
Yabe, Michitoshi
Kenmotsu, Hirotsugu
Matsuda, Suguru
Morita, Meiko
Sekikawa, Motoki
Doshita, Kosei
Kodama, Hiroaki
Miura, Keita
Morikawa, Noboru
Yuko, Iida
Mamesaya, Nobuaki
Kobayashi, Haruki
Ko, Ryo
Wakuda, Kazushige
Ono, Akira
Murakami, Haruyasu
Naito, Tateaki
Takahashi, Toshiaki
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[27] A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN PATIENTS WITH RESECTED EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER IN PORTUGAL
Andrade, A.
Tavares, A. L.
VALUE IN HEALTH, 2023, 26 (12) : S64 - S64
[28] Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study
Hochmair, Maximilian J.
Morabito, Alessandro
Hao, Desiree
Yang, Cheng-Ta
Soo, Ross A.
Yang, James C-H
Gucalp, Rasim
Halmos, Balazs
Wang, Lara
Maerten, Angela
Cufer, Tanja
FUTURE ONCOLOGY, 2019, 15 (25) : 2905 - 2913
[29] COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
Holleman, M. S.
Al, M. J.
Uyl-de Groot, C. A.
VALUE IN HEALTH, 2018, 21 : S3 - S3
[30] A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
Igawa, Satoshi
Kasajima, Masashi
Ono, Taihei
Ozawa, Takahiro
Kakegawa, Mikiko
Kusuhara, Seiichiro
Sato, Takashi
Nakahara, Yoshiro
Fukui, Tomoya
Yokoba, Masanori
Kubota, Masaru
Mitsufuji, Hisashi
Sasaki, Jiichiro
Naoki, Katsuhiko
CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8695 - 8705

← 1 2 3 4 5 →